For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 11,175 | 9,229* | 8,454 | 7,873 |
| General and administrative | 3,702 | 2,495* | 2,118 | 2,387 |
| Total operating expenses | 14,877 | 11,723 | 10,572 | 10,260 |
| Loss from operations | -14,877 | -11,723* | -10,572 | -10,260 |
| Interest income and other expense, net | 1,784 | 440* | 738 | 639 |
| Change in fair value of warrant liability | - | -24,123* | - | -2,012 |
| Gain before equity method investment | -13,093 | 12,840* | -9,834 | -7,609 |
| Loss from equity method investment | -599 | -890* | -323 | -389 |
| Net (gain) income | -13,692 | 11,950* | -10,157 | -7,998 |
| Unrealized loss on marketable securities | -334 | -32* | 29 | -19 |
| Cumulative foreign currency translation adjustment | 104 | 133* | 59 | 125 |
| Comprehensive (gain) income | -13,922 | 12,051 | -10,069 | -7,892 |
| Basic EPS | -0.15 | 0.158 | -0.12 | -0.1 |
| Diluted EPS | -0.15 | 0.153 | -0.12 | -0.1 |
| Basic Average Shares | 89,996,728 | 76,283,813 | 82,836,369 | 77,774,344 |
| Diluted Average Shares | 89,996,728 | 78,617,342 | 82,836,369 | 77,774,344 |
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)